To compare combination therapy with bicalutamide 80 mg and a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A alone in Japanese men with untreated advanced prostate cancer. A total of 205 patients with stage C/D prostate cancer were randomized to either LHRH-A þ once-daily oral bicalutamide 80 mg or placebo. Primary study variables have been reported previously. Secondary variables included: time to achieve prostate-specific antigenp4 ng/ ml, time-to-treatment failure (TTTF), time-to-disease progression (TTP), overall survival (OS), adverse events and adverse drug reactions. Following combination therapy with bicalutamide 80 mg, there were significant (Po0.001) advantages over LHRH-A alone in terms of TTTF and TTP, but the difference in the interim OS was not statistically significant. First-line combination therapy with bicalutamide 80 mg in Japanese patients with advanced prostate cancer offers significant benefits over LHRH-A alone, with respect to TTTF and TTP. Follow-up for OS continues.
Introduction
Combined androgen blockade (maximum androgen blockade), consisting of an antiandrogen plus either a luteinizing hormone-releasing hormone agonist (LHRH-A) or orchiectomy, is standard care in Japan for patients with advanced prostate cancer. 1, 2 Although the rationale for administering combination therapy is strong, results from individual clinical studies have been mixed. 3 The Prostate Cancer Trialists' Collaborative Group (PCTCG) conducted a meta-analysis of all available randomized trials (27 studies) of combination therapy versus castration alone. 4 The results of this large analysis (n ¼ 8275) demonstrated a small but statistically significant survival benefit, with the addition of a nonsteroidal antiandrogen (nilutamide or flutamide), to castration monotherapy (P ¼ 0.005). Conversely, combination therapy with the steroidal antiandrogen cyproterone acetate was associated with a 13% increase in the risk of death (P ¼ 0.04).
First approved in 1995, bicalutamide is a nonsteroidal antiandrogen. A Phase III study to assess the efficacy of bicalutamide 50 mg combination therapy was initiated in Caucasian men using a flutamide combination regimen, which was considered standard care at that time, as the active comparator. 5 The results demonstrated that bicalutamide 50 mg combination therapy was at least as effective as flutamide combination therapy. In addition, the bicalutamide regimen was better tolerated, with a significantly lower rate of diarrhea (Po0.001) and fewer withdrawals due to adverse events.
Using data from the study conducted by Schellhammer et al., 5 together with findings from the PCTCG meta-analysis, 4 a retrospective analysis was recently conducted to indirectly assess the efficacy of bicalutamide 50 mg combination therapy with that of castration alone. This analysis demonstrated that bicalutamide 50 mg combined with castration results in a 20% reduction in the risk of mortality compared with castration alone. This estimated benefit is larger than that observed with the other antiandrogens in the PCTCG analysis.
To date, only three studies have investigated combination hormonal therapy in Japanese men with advanced prostate cancer. Two of these studies assessed combination therapy using the steroidal antiandrogen chlormadinone acetate, and one used the nonsteroidal antiandrogen flutamide. Neither of the steroidal antiandrogen studies showed an improvement in overall survival (OS) with combination therapy compared with LHRH-A alone. 6, 7 The use of the nonsteroidal antiandrogen flutamide combined with an LHRH-A was studied in 161 Japanese patients. 8 In this unblinded study, combination therapy was superior to LHRH-A monotherapy in terms of reduction of prostate-specific antigen (PSA) level and time to PSA progression.
To further elucidate the effect of adding an antiandrogen to LHRH-A, we initiated a randomized, doubleblind, multicenter study. As bicalutamide has good compliance and tolerability findings, it was selected for investigation in this study. 9 In most countries, bicalutamide is given at a dose of 50 mg when used in combination with an LHRH-A. However, based on pharmacokinetic and pharmacodynamic data, the approved dose of bicalutamide in Japanese men is 80 mg per day. We had previously conducted a pilot study of LHRH-A in combination with bicalutamide 80 mg per day, which identified no significant safety concerns. 10 Therefore, we selected the 80 mg dose for our phase III study in Japanese men. 11, 12 Primary efficacy findings (median follow-up 66 weeks) from this phase III study have previously been reported in an interim publication. 9 At 12-weeks following treatment initiation, bicalutamide 80 mg combination therapy significantly improved the proportion of patients achieving PSA levels of p4 ng/ml compared with LHRH-A alone (79.4 versus 38.6%, respectively; Po0.001). Bicalutamide also improved 12-week overall tumor-response rates compared with LHRH-A alone (77.5 versus 65.3%, respectively; P ¼ 0.063). Importantly, safety was not compromised with the addition of a second therapy (withdrawal rate due to adverse drug reactions 8.8% bicalutamide versus 10.9%, LHRH-A alone). This is the first double-blind, controlled clinical trial to assess bicalutamide combination therapy versus castration alone, in men with prostate cancer. Here, we report a longer-term analysis of the secondary outcome variables from this study, at a median of 127 weeks. We discuss time to achieve a PSA level of p4 ng/ml, time-totreatment failure (TTTF), time-to-disease progression (TTP), OS and the incidence of adverse events and adverse drug reactions. These results were first presented in brief at the American Society of Oncology (ASCO) annual meeting in 2005. Treatment responses subsequent to disease progression, including antiandrogen withdrawal syndrome and responses to second-line bicalutamide 80 mg treatment are also discussed.
Patients and methods

Study design and treatment
Financial sponsorship for this trial was provided by AstraZeneca. The design of this randomized, doubleblind, multicenter trial has been reported previously. 9 All patients received LHRH-A (goserelin acetate 3.6 mg or leuprorelin acetate 3.75 mg) by subcutaneous depot injection every 4 weeks. Patients were randomized 1:1 to either oral bicalutamide 80 mg or matching placebo, once daily, using a double-blind method. As the minimum duration of follow-up time exceeded 6 months, the code was broken in September 2002 for ethical reasons. Subsequently, patients in the LHRH-A only group discontinued placebo and received LHRH-A alone, and patients in the bicalutamide 80 mg combination therapy group continued combination therapy in an open-label manner. Combination therapy was continued until November 2003, or until either disease progression or other withdrawal criterion occurred.
If a patient in the combined therapy group experienced disease progression during open-label treatment, bicalutamide was discontinued and the patient was monitored for antiandrogen withdrawal syndrome. Any subsequent therapy was initiated at the investigator's discretion. Patients in the LHRH-A only group who had disease progression were treated at the investigator's discretion, with addition of bicalutamide 80 mg being an option.
Patients
Patients with histologically confirmed, previously untreated advanced (stage C/D) prostate cancer were recruited, February 2000-December 2001, at 49 Japanese centers. Inclusion and exclusion criteria have been described previously. 9 All patients provided written, informed consent before enrolment.
The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and Good Clinical Practice requirements. The protocol was approved at all participating institutions by an Institutional Review Board. An Independent Data Monitoring Committee was established to conduct annual interim assessments of findings from the study.
Assessments
The primary lesion and metastatic sites were assessed clinically and by appropriate imaging techniques (scintigraphy, computed tomography, magnetic resonance imaging, ultrasound, X-ray) at baseline, 12 weeks and as appropriate. Efficacy assessments were performed, as described previously, 9 and were measured at baseline, weeks 1, 4, 5, 8 and 12 after the start of treatment, and then every 4 weeks until either disease progression or treatment withdrawal. Following this, patients were evaluated annually for progression and survival. Outcome variables were established using the Japanese Urological Association Criteria, edition 2.
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Details of adverse events were recorded at each visit and up to 4 weeks after treatment withdrawal. Events for which a causal relationship to the study drug(s) could not be excluded were classified as adverse drug reactions.
Outcome variables and statistical analysis
All patients who received at least one dose of study medication were included in the safety and primary efficacy analyses (intention-to-treat analysis).
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The primary study variables were the PSA normalization rate (defined as the proportion of patients with a normal (p4 ng/ml) PSA level) and overall tumorresponse rate (defined as the proportion of patients with a partial response or better) at 12 weeks and the rate of withdrawals due to adverse drug reactions at the time of data cutoff (January 22, 2004) . Calculations on the sample size required assumed that these variables would be similar to those observed in previous studies. 9 The percentage of withdrawals due to adverse drug reactions in the combined androgen blockade (CAB) group was considered clinically acceptable if the upper limit of the 95% confidence interval (CI) for the difference between the two treatment groups was o12.5%. Based on these assumptions, the required sample size (90% power, twosided significance level of 0.05) was 200 patients (100 in each treatment group).
Secondary variables were: time to achieve PSA levels of p4 ng/ml; TTTF; TTP; OS; quality-of-life (to be reported elsewhere); and the incidence of adverse events/adverse drug reactions. TTTF was defined as the number of days between the first dose of the study treatment (earliest of LHRH-A or randomized therapy) and the earliest of study treatment withdrawal, disease progression or death. TTP was defined as the number of days between the first dose of study treatment and either disease progression or prostate cancer death. The relapse of primary lesion and/or metastatic sites assessed by imaging techniques, and/or PSA relapse (e.g. increases at three consecutive measurements) were judged to be disease progression.
Following disease progression and discontinuation of bicalutamide in the combination group, no change in PSA or reduced PSA levels were described as antiandrogen withdrawal responses. Among patients who had disease progression following LHRH-A alone, and were subsequently given bicalutamide 80 mg in an open-label fashion, a X50% reduction in PSA levels constituted a response to second-line combination treatment.
The Cox proportional hazards model was used to analyze the time-to-event data. In addition, time to achieve PSA p4 ng/ml, TTTF and TTP were compared between the treatment groups using the log-rank test.
Results
Patient demographics and dispositions
Patients (n ¼ 205) were randomized to either bicalutamide 80 mg combination therapy (n ¼ 102) or LHRH-A alone (n ¼ 103). Two patients in the LHRH-A only arm withdrew before therapy. As reported previously, patient demographics for the two treatment groups were well matched (Table 1) .
Treatment was discontinued early in 54/102 patients who received bicalutamide 80 mg combination therapy, and in 78/101 of the patients who received LHRH-A alone (Figure 1 ). Only one patient, who received combination therapy, could be not followed-up for efficacy.
Efficacy variables
Here, we report the effect of bicalutamide on the secondary efficacy variables of the study at a median follow-up of 127 weeks (Table 2) .
Time to achieve a prostate-specific antigen level of p4 ng/ml. Time to achieve a PSA level of p4 ng/ml was significantly shorter with bicalutamide 80 mg combination therapy than with LHRH-A alone (8.1 weeks versus 24.1 weeks, respectively; hazard ratio (HR) 3.96; 95% CI 2.77-5.66; Po0.001) and occurred in 96/102 (94.1%) patients in the combination therapy arm and 59/ 101 (58.4%) patients in the LHRH-A only arm (Po0.001).
Time-to-treatment failure. Time-to-treatment failure was significantly longer with bicalutamide 80 mg combination therapy than with LHRH-A alone (Figure 2 ). Treatment failure occurred in 54/102 (52.9%) patients at a median of 117.7 weeks in the combination therapy group and in 78/101 (77.2%) patients at a median of 60.3 weeks in the LHRH-A only group (HR 0.54; 95% CI 0.38-0.77; Po0.001). Figure 3 ). The median TTP in the LHRH-A group was 96.9 weeks; the median TTP has yet to be reached in the combination group. Time-to-disease progression among patients with different stages of prostate cancer was investigated as part of an exploratory analysis. A greater effect was seen in bicalutamide 80 mg combination therapy versus LHRH-A alone in the 99 patients with stage C locally advanced disease (134.1 weeks versus median TTP not yet reached, Po0.001; Figure 4 ).
Overall survival. To date, 13/102 (12.7%) patients in the bicalutamide 80 mg combination group and 18/101 (17.8%) in the LHRH-A only group have died. The disease-specific survival findings were similar for the treatment groups ( Figure 5 ).
Exploratory analysis of combined PSA data from the treatment groups demonstrated a significantly lower disease-specific mortality rate among patients who 
LHRH-A þ bicalutamide versus LHRH-A monotherapy M Usami et al
achieved a PSA level p4 ng/ml at 12 weeks, compared with patients who did not (HR 0.15; 95% CI 0.06-0.38; Po0.001; Figure 6 ).
Responses subsequent to disease progression
Eighteen patients consented to undergo follow-up for antiandrogen withdrawal syndrome: seven (38.9%) had a reduced/unchanged PSA after discontinuing bicalutamide. The median time to response in these seven patients was 6.9 weeks and the effect lasted for a median of 58.1 weeks.
Among patients who received LHRH-A only, before relapse, 31/40 (77.5%) experienced decreased PSA levels after adding bicalutamide 80 mg (i.e. X50% reduction in PSA following relapse). The median times to, and duration of, response with second-line bicalutamide 80 mg combination therapy were 4.1 weeks and 39.6 weeks, respectively.
Tolerability
Bicalutamide 80 mg combination therapy had a tolerability profile similar to LHRH-A alone (Table 3) . Withdrawals due to adverse drug reactions were comparable: 8.8% (9/102) of patients in the combination therapy group withdrew, whereas 10.9% (11/101) in the LHRH-A only group (95% CI on difference: À10.7-6.4). Figure 6 Disease-specific survival for patients achieving PSA levels of p4 ng/ml at 12 weeks versus those not achieving PSA levels of p4 ng/ml at 12 weeks. Hazard ratio 0.15; 95% CI 0.06-0.38; Po0.001; PSA, prostate-specific antigen.
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Discussion
This trial is the world's first double-blind controlled study to directly compare bicalutamide plus LHRH-A versus LHRH-A alone in men with prostate cancer. Once-daily bicalutamide 80 mg in combination with LHRH-A provided superior efficacy to LHRH-A alone in terms of time to achieve PSA levels of p4 ng/ml, TTTF and TTP. Notably, the median TTP has still not been reached among patients receiving bicalutamide 80 mg combination therapy, but was 96.9 weeks among men in the LHRH-A only arm. Additionally, the differences in TTTF and TTP between the two treatment groups were greater than those observed in an earlier analysis, 9 indicating that the advantage seen with bicalutamide 80 mg combination therapy has become more pronounced with increased follow-up.
These findings are supported by those reported in an earlier interim analysis from this study, which showed that at 12 weeks, patients receiving bicalutamide 80 mg combination therapy are significantly more likely to achieve PSA levels of p4 ng/ml and have higher overall tumor-response rates than those receiving LHRH-A alone. 9 An exploratory analysis revealed that the effect of bicalutamide 80 mg therapy on TTP is most pronounced in patients with locally advanced disease (stage C). The baseline characteristics of the two treatment groups were well balanced among patients with stage C disease. This suggests that although combination therapy using bicalutamide 80 mg has the potential to benefit all patients with advanced/locally advanced disease, the benefit over castration alone is greatest for patients with locally advanced tumors without spread to the lymph nodes or elsewhere.
There was no significant difference between the bicalutamide 80 mg combination therapy arm and the LHRH-A only arm in terms of OS/disease-specific survival at this analysis. This was not unexpected, as the mortality rates remain low in both treatment arms. Long-term follow-up of patients will be continued to show if there is any correlation between the choice of treatment and a reduced risk of death. Findings from an additional exploratory analysis of this data suggest that this is likely to be the case. The exploratory analysis revealed an association between levels of PSA p4 ng/ml at 12 weeks and a lower risk of death caused by prostate cancer. This, taken alongside the primary trial finding that bicalutamide 80 mg combination therapy significantly improves the proportion of patients achieving PSA levels of p4 ng/ml at 12 weeks relative to LHRH-A alone, demonstrates that bicalutamide 80 mg combination therapy has strong potential to improve survival. The likelihood that bicalutamide 80 mg combination therapy can improve OS versus castration alone is further supported by the findings from a recent indirect analysis by Klotz et al. 3 In this analysis, bicalutamide 50 mg plus LHRH-A was associated with a 20% reduction in mortality risk compared with LHRH-A alone.
Most patients with advanced prostate cancer who initially respond to combination therapy with an antiandrogen plus castration will, ultimately, experience disease progression. However, following subsequent withdrawal of antiandrogen therapy, some patients will experience a decrease in serum PSA levels and develop an antitumor response. This well-recognized phenomenon is referred to as the antiandrogen withdrawal syndrome and has also been described for patients who have received other nonsteroidal antiandrogens. [14] [15] [16] Indeed, a PSA response following withdrawal of nonsteroidal antiandrogen therapy (including with bicalutamide) typically occurs in approximately 15-36% of patients, and is characterized by a X50% decrease in PSA for 4-7 months. 17, 18 In this trial, 39% of patients had a PSA response (no change or a decrease in PSA levels) following discontinuation of bicalutamide 80 mg, and responses lasted for a median of 58 weeks. One explanation of why the PSA response rate following bicalutamide withdrawal was higher in this study, than in others, is that our definition of response was different to that used in other studies.
In those men who experienced disease progression following first-line LHRH-A alone, 78% (31/40) responded to the addition of bicalutamide 80 mg treatment. The efficacy of second-line bicalutamide 80 mg combination therapy in men with prostate cancer could suggest that combination therapy should only be used following initial therapy with castration alone. However, the median duration of response to second-line bicalutamide 80 mg was 40 weeks, and the median TTP following LHRH-A alone was 97 weeks, indicating a combined total TTP of 137 weeks. In contrast, based on current findings, the median TTP in patients receiving first-line bicalutamide 80 mg combination therapy is expected to be greater than the median TTP of 137 weeks calculated for patients receiving delayed bicalutamide 80 mg combination therapy (to date, o50% of patients have experienced progression). Therefore, we would expect bicalutamide 80 mg combination to be more effective as a first-line approach than as a secondline approach.
Importantly, in our trial, combination of bicalutamide 80 mg with LHRH-A did not lead to a rise in toxicity or withdrawals compared with LHRH-A alone. The rates of LHRH-A þ bicalutamide versus LHRH-A monotherapy M Usami et al withdrawal due to adverse drug reactions were also similar for the two treatment groups. As in the earlier analysis, the most common adverse events, occurring with similar incidence in both treatment arms, were nasopharyngitis and hot flushes. Although the reason for the relatively high incidence of nasopharyngitis is not clear, the incidence of nasopharyngitis that was attributed to adverse drug reactions was very low (1.0% in both groups). Less than 7% of patients in the bicalutamide 80 mg combination therapy group had gastrointestinal symptoms (constipation 6.9%, nausea 5.9% and diarrhea 4.9%), which was comparable to that observed in the LHRH-A only arm (11.9, 3.0 and 4.0%, respectively). The incidence of gastrointestinal adverse events among patients receiving bicalutamide 80 mg was lower than predicted from studies with bicalutamide 50 mg combination therapy in Caucasians, 5 but reflected the low incidence reported in the earlier analysis of our study. 5, 9 As expected from previous studies of hormonal combination therapy, 19 the incidences of breast pain and gynecomastia were also low, occurring in only three men in the bicalutamide 80 mg combination group, and in no men in the LHRH-A alone group.
The tolerability profile of bicalutamide makes it an attractive agent for use in hormonal combination regimens, particularly as the profile is favorable compared with other antiandrogens. 17, 20 Compared with bicalutamide, flutamide carries a higher risk of gastrointestinal events and hepatotoxicity; nilutamide is associated with delayed adaptation to darkness, alcohol intolerance and interstitial pneumonitis; and steroidal antiandrogens carry a risk of hepatotoxicity, cardiovascular events, reduced sexual potency and adverse serum lipid changes.
In summary, among Japanese men with advanced prostate cancer, first-line treatment with a combination of bicalutamide 80 mg and an LHRH-A provides significant efficacy benefits over LHRH-A alone, without increasing the incidence of adverse events or reducing tolerability. Patients continue to be followed for OS.
